Pegylated interferon alpha 2b for treatment of ocular surface squamous neoplasia: A pilot study

Research output: Contribution to journalArticle

12 Scopus citations

Abstract

Purpose: To conduct a pilot study of pegylated interferon alpha 2b (PEGIFNα2b) for treatment of ocular surface squamous neoplasia (OSSN). Methods: Three patients with histologically proven OSSN were studied prospectively. Patients were given subconjunctival/perilesional injections of 1μg/kg of PEGIFNα2b (PEG Intron, Schering-Plough, Kenilworth, NJ) until the tumor resolved. Patients were followed clinically and photographically for evidence of tumor resolution and recurrence. Results: All patients had clinical resolution of the tumor. The mean time to resolution was 47 days. During the follow-up time after resolution of the lesion (mean 41 months), one patient had disease recurrence 7 months after clinical resolution. This was successfully treated with one further injection. Conclusion: PEGIFNα2b may be a viable medical alternative for the treatment of OSSN. Future studies will be needed to evaluate whether PEGIFNα2b is as effective as recombinant interferon alpha 2b.

Original languageEnglish (US)
Pages (from-to)254-260
Number of pages7
JournalOcular Immunology and Inflammation
Volume18
Issue number4
DOIs
StatePublished - Aug 1 2010

Keywords

  • Conjunctival intraepithelial neoplasia
  • Ocular surface squamous neoplasia
  • Pegylated interferon

ASJC Scopus subject areas

  • Ophthalmology
  • Immunology and Allergy

Fingerprint Dive into the research topics of 'Pegylated interferon alpha 2b for treatment of ocular surface squamous neoplasia: A pilot study'. Together they form a unique fingerprint.

  • Cite this